Guerbet Restructures Board for Improved Governance
Guerbet, a global leader in medical imaging, has initiated significant changes within its Board of Directors. These modifications come as part of the company’s continued commitment to strong corporate governance and effective leadership.
Key Changes in the Board Composition
During a recent Annual General Meeting, key decisions were made to strengthen the board. The following adjustments were approved:
- Reorganization of the Board of Directors
- Reduction of directors' terms to four years
- Appointment of new independent directors
- Reappointment of two existing directors
Adjustment of Directors' Terms
The board voted to reduce the duration of directors' terms from six years to four years. This change is in line with the Afep-Medef Code recommendations for corporate governance in listed companies. It applies to both newly appointed and current directors.
As a result of this transition, several directors completed their terms during the meeting, including Claire Jouault Massiot, Céline Lamort, Mark Fouquet, Didier Izabel, and Jean-Sébastien Raynaud. Additionally, Pascale Auger voluntarily resigned from her post, allowing for a fresh perspective on the board.
New Appointments and Reappointments
The Annual General Meeting took this opportunity to welcome new independent directors. Michèle Lesieur was appointed for a three-year term, bringing a wealth of knowledge from her extensive background in the healthcare sector. She has led significant projects at the Philips Group and held pivotal roles in various medical imaging firms.
Furthermore, Eric Drapé was appointed as an independent director for a four-year term. His experience includes notable positions at Teva Pharmaceuticals and extensive international exposure across the pharmaceutical industry, which will provide valuable insights into Guerbet's strategic direction.
Continuity With Reappointments
Guerbet also reappointed Céline Lamort and Marc Massiot as directors, securing continuity in the board's vision and initiatives. Lamort has been a part of the board since 2015, whereas Massiot joined in 2021, representing the company’s majority stakeholder.
Current Composition of the Board
With the recent changes, the board now comprises nine members, a reduction from twelve, reflecting a more streamlined approach to governance:
- Hugues Lecat - Chairman, Independent Director
- Carine Dagommer - Director
- Eric Drapé - Independent Director
- Marie de la Simone - Employee Director
- Eric Guerbet - Director
- Céline Lamort - Director
- Michèle Lesieur - Independent Director
- Nicolas Louvet - Director
- Marc Massiot - Director
The board expresses heartfelt gratitude to former directors for their commitment and contributions. It looks forward to leveraging the expertise of newly appointed directors to further Rome’s leadership in the medical imaging sector.
Guerbet's Vision and Commitment
At Guerbet, the mission revolves around enhancing lives through superior medical imaging solutions. As a pioneer in this field for nearly a century, Guerbet dedicates about 9% of its sales to research and development. The company continues to innovate through a full spectrum of pharmaceutical products, medical devices, and digital solutions—including AI applications.
Guerbet operates globally with over 2,905 employees and is listed on Euronext Paris under ticker GBT. Last year, the company generated substantial revenue, showcasing its strong market position and forward-thinking approach.
Frequently Asked Questions
What recent changes were made to Guerbet's Board of Directors?
Guerbet announced several updates, including a reorganization of the board, a reduction in directors' terms to four years, and new appointments of independent directors.
Who were the new members appointed to the Board?
Michèle Lesieur and Eric Drapé have been appointed as independent directors, bringing significant experience from the healthcare and pharmaceutical sectors.
How long are the new terms for directors at Guerbet?
The Board of Directors' terms have been adjusted to a four-year duration, aligning with corporate governance recommendations.
What is Guerbet's main area of expertise?
Guerbet is a leader in medical imaging, specializing in contrast media and offering a range of pharmaceutical products and devices for diagnostic imaging.
How does Guerbet support innovation in the healthcare sector?
Guerbet invests around 9% of its sales in research and development, focusing on innovation in medical imaging technologies and solutions.
